leisure time -WSS

leisure time

author：explore 2025-09-30 01:02:52 - browse：39

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： What it’s like to watch children die of measles

focus

WSS

Medicare inequities exacerbate Puerto Rico’s health disparities

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Novo Nordisk obesity pill bests Wegovy in early trial

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Precocious puberty in girls comes with mental health risks

A deep dive into Applied Therapeutics’ data, and questions on Cassava

hotspot

leisure time

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Guidelines to prevent youth baseball injuries need more muscle

The Harvard botanist who searched for psychedelics in the Amazon

New air purifier tech could be key to improving indoor air quality

Obesity drugs seen as possible treatment for liver disease MASH

Peter Hotez and the public health issue of online harassment

With competition flaring, obesity drug hits goal in liver disease study

Activists slam private health insurers over coverage restrictions

Obesity drugs seen as possible treatment for liver disease MASH

hotspot

With competition flaring, obesity drug hits goal in liver disease study

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

CDC marks new Covid

The problem with charging patients to message their doctors

R1 RCM gets $5.8 billion buyout offer from private equity firm

The drug industry has found itself all alone in Washington

focus

Wikipedia

focus

Wikipedia